

## BACKGROUND AND OBJECTIVES

In preclinical stages of Alzheimer's disease (AD), questions remain about relationships between cerebrospinal fluid (CSF) amyloid beta (A $\beta$ ) and *tau* proteins, and other markers of AD pathogenesis. In the PREVENT-AD cohort of cognitively normal older adults with a parental history of AD-like dementia, we assessed CSF A $\beta$  and *tau* in relation to brain integrity and cognitive function.

## METHODS

### Cohort

Cognitively normal older adults with a family history of AD

n=105	Age (years)	Male (%)	Education (years)
	63 $\pm$ 5	29	15 $\pm$ 3

### CSF Measurements

Amyloid-beta 42 and 40 (A $\beta$ <sub>1-42</sub> and A $\beta$ <sub>1-40</sub>), phosphorylated tau (P-*tau*)

### Neuroimaging

Hippocampal volume adjusted for total intracranial volume


### Cognition

- Repeatable Battery for Assessment of Neuropsychological Status (RBANS) total score
- Subjective cognitive decline: Self-reported change in memory compared to 20 years ago

### Statistical analyses

General linear models with age as a covariate

## DISTRIBUTIONS OF CSF A $\beta$ AND P-*tau*




Cutoff at the 25th percentile

High A $\beta$  pathology:


CSF A $\beta$ <sub>1-42</sub> < 845

Low A $\beta$  pathology:

CSF A $\beta$ <sub>1-42</sub> > 845



## RELATIONSHIPS BETWEEN HIPPOCAMPAL VOLUME AND CSF MARKERS



Low A $\beta$  pathology  $R^2 = 0.01$   
High A $\beta$  pathology  $R^2 = 0.28$

Amyloid groups,  $p=0.07$


P-*tau*,  $p=0.20$

Interaction,  $p=0.02$

There was an interaction between P-*tau* and amyloid on the hippocampal volume: individuals with high amyloid pathology (low CSF A $\beta$ <sub>1-42</sub>) present a lower hippocampal volume with higher P-*tau* level.


## RELATIONSHIPS BETWEEN COGNITION AND CSF MARKERS

### SUBJECTIVE COGNITIVE DECLINE



Binary logistic regression: High amyloid pathology is associated ( $p=0.05$ ) with reporting worsening of one's memory compared to 20 years ago.

### OBJECTIVE COGNITIVE SCORE



Low A $\beta$  pathology  $R^2 = 0.04$   
High A $\beta$  pathology  $R^2 = 0.06$

Amyloid groups,  $p=0.80$

P-*tau*,  $p=0.06$

Interaction,  $p=0.78$

There was no interaction between A $\beta$  groups and P-*tau* on cognitive performance, although total RBANS score declines with elevated P-*tau* at trend level.


## CONCLUSIONS

There are already detectable relations between CSF biomarkers, hippocampal volume and subjective cognitive decline in cognitively normal, asymptomatic elderly, driven mainly by individuals with high P-*tau* and low A $\beta$ <sub>1-42</sub> levels.

## FUTURE WORK

Recent literature suggests that the ratio of CSF A $\beta$ <sub>42</sub>/A $\beta$ <sub>40</sub> might be more sensitive to AD pathology (Janelidze et al., *Annals Clin Transl Neurol*, 2016) and predict better amyloid accumulation in the brain over to years (Racine et al., *Alzheimer's and Dementia*, 2016) than A $\beta$ <sub>42</sub> alone. We are starting to investigate the effects of using such a ratio in our analyses.

Specifically, we looked at the difference between the relationships of amyloid and P-*tau*, using either CSF A $\beta$ <sub>42</sub> or A $\beta$ <sub>42</sub>/A $\beta$ <sub>40</sub>.




ApoE4-  $R^2 = 0.35$   
ApoE4+  $R^2 = 0.08$

ApoE4,  $p=0.03$

P-*tau*,  $p=0.02$

Interaction,  $p<0.001$

The association between levels of A $\beta$  and P-*tau* was clearly dependent on APOE- $\epsilon$ 4 status (interaction  $p<0.001$ ). In  $\epsilon$ 4 carriers, we observed an expected relationship of higher A $\beta$  pathology (lower CSF values) with higher P-*tau*, but the inverse was found in non-carriers.



ApoE4-  $R^2 = 0.01$   
ApoE4+  $R^2 = 0.11$

ApoE4,  $p=0.37$

P-*tau*,  $p=0.26$

Interaction,  $p=0.06$

When using the ratio A $\beta$ <sub>42</sub>/A $\beta$ <sub>40</sub>, the previous interaction is not significant anymore, but we still observed the same relationship in  $\epsilon$ 4 carriers.